UCB has announced that it will build a multi-product biological manufacturing facility on its site in Braine l’Alleud, Wallonia, Belgium. The new biotechnology plant is being constructed to accompany the company’s growth and prepare for the launch and long-term supply of future medicines currently in clinical development.  

The new facility, representing an investment of more than EUR 300 million ($336 million) over the coming years, is expected to be operational in 2024. Construction is due to start in the first quarter of 2020.

The company says that the shift of its pipeline toward large molecules requires it to ramp up investment in mammalian technical development as well as its manufacturing capabilities. UCB says it expects to create more than 150 new, high-skilled jobs once the plant becomes fully operational.

Source: UCB